CN113317421A - Beverage composition for conditioning dysmenorrhea and preparation method thereof - Google Patents
Beverage composition for conditioning dysmenorrhea and preparation method thereof Download PDFInfo
- Publication number
- CN113317421A CN113317421A CN202110593077.4A CN202110593077A CN113317421A CN 113317421 A CN113317421 A CN 113317421A CN 202110593077 A CN202110593077 A CN 202110593077A CN 113317421 A CN113317421 A CN 113317421A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- conditioning
- beverage composition
- dysmenorrheal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 102
- 235000013361 beverage Nutrition 0.000 title claims abstract description 86
- 230000003750 conditioning effect Effects 0.000 title claims abstract description 76
- 206010013935 Dysmenorrhoea Diseases 0.000 title claims abstract description 55
- 208000005171 Dysmenorrhea Diseases 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title description 3
- 240000001717 Vaccinium macrocarpon Species 0.000 claims abstract description 46
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 claims abstract description 45
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 claims abstract description 45
- 235000004634 cranberry Nutrition 0.000 claims abstract description 45
- 244000124853 Perilla frutescens Species 0.000 claims abstract description 39
- 235000004347 Perilla Nutrition 0.000 claims abstract description 38
- 241001506047 Tremella Species 0.000 claims abstract description 37
- 150000004676 glycans Chemical class 0.000 claims abstract description 35
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 35
- 239000005017 polysaccharide Substances 0.000 claims abstract description 35
- 102000016942 Elastin Human genes 0.000 claims abstract description 34
- 108010014258 Elastin Proteins 0.000 claims abstract description 34
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 34
- 229920002549 elastin Polymers 0.000 claims abstract description 34
- 235000008397 ginger Nutrition 0.000 claims abstract description 34
- 239000000212 ceratonia siliqua l. fruit extract Substances 0.000 claims abstract description 33
- 239000000843 powder Substances 0.000 claims abstract description 32
- 241000269851 Sarda sarda Species 0.000 claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 claims abstract description 21
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 43
- 239000003765 sweetening agent Substances 0.000 claims description 43
- 239000000686 essence Substances 0.000 claims description 42
- 239000000706 filtrate Substances 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 238000003756 stirring Methods 0.000 claims description 35
- 241000133134 Saussurea Species 0.000 claims description 33
- 239000003381 stabilizer Substances 0.000 claims description 28
- 238000010438 heat treatment Methods 0.000 claims description 27
- 238000001914 filtration Methods 0.000 claims description 18
- 230000001954 sterilising effect Effects 0.000 claims description 18
- 238000001816 cooling Methods 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 13
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000004576 sand Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- 229920000858 Cyclodextrin Polymers 0.000 claims description 9
- 241000109329 Rosa xanthina Species 0.000 claims description 9
- 235000004789 Rosa xanthina Nutrition 0.000 claims description 9
- 238000009835 boiling Methods 0.000 claims description 9
- 235000021552 granulated sugar Nutrition 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 238000005086 pumping Methods 0.000 claims description 9
- 238000002791 soaking Methods 0.000 claims description 9
- 238000003860 storage Methods 0.000 claims description 9
- 239000001116 FEMA 4028 Substances 0.000 claims description 8
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 8
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 8
- 229960004853 betadex Drugs 0.000 claims description 8
- 239000001509 sodium citrate Substances 0.000 claims description 8
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 8
- 238000005507 spraying Methods 0.000 claims description 8
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 7
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 7
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 7
- 239000000811 xylitol Substances 0.000 claims description 7
- 235000010447 xylitol Nutrition 0.000 claims description 7
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 7
- 229960002675 xylitol Drugs 0.000 claims description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 6
- 229920001817 Agar Polymers 0.000 claims description 6
- 239000008272 agar Substances 0.000 claims description 6
- 235000010419 agar Nutrition 0.000 claims description 6
- 239000001530 fumaric acid Substances 0.000 claims description 6
- 239000004310 lactic acid Substances 0.000 claims description 6
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- 235000010413 sodium alginate Nutrition 0.000 claims description 6
- 239000000661 sodium alginate Substances 0.000 claims description 6
- 229940005550 sodium alginate Drugs 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- 229920001285 xanthan gum Polymers 0.000 claims description 6
- 235000010493 xanthan gum Nutrition 0.000 claims description 6
- 239000000230 xanthan gum Substances 0.000 claims description 6
- 229940082509 xanthan gum Drugs 0.000 claims description 6
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 5
- 239000001630 malic acid Substances 0.000 claims description 5
- 235000011090 malic acid Nutrition 0.000 claims description 5
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 4
- 239000004386 Erythritol Substances 0.000 claims description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 239000004378 Glycyrrhizin Substances 0.000 claims description 4
- 229920002907 Guar gum Polymers 0.000 claims description 4
- 239000004376 Sucralose Substances 0.000 claims description 4
- 235000010410 calcium alginate Nutrition 0.000 claims description 4
- 239000000648 calcium alginate Substances 0.000 claims description 4
- 229960002681 calcium alginate Drugs 0.000 claims description 4
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims description 4
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 4
- 235000019414 erythritol Nutrition 0.000 claims description 4
- 229940009714 erythritol Drugs 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 4
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 4
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 4
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 4
- 235000010417 guar gum Nutrition 0.000 claims description 4
- 239000000665 guar gum Substances 0.000 claims description 4
- 229960002154 guar gum Drugs 0.000 claims description 4
- 239000000905 isomalt Substances 0.000 claims description 4
- 235000010439 isomalt Nutrition 0.000 claims description 4
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 235000019408 sucralose Nutrition 0.000 claims description 4
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 4
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 3
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 3
- 229960004998 acesulfame potassium Drugs 0.000 claims description 3
- 239000000619 acesulfame-K Substances 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 235000011087 fumaric acid Nutrition 0.000 claims description 3
- 235000011083 sodium citrates Nutrition 0.000 claims description 3
- 244000228451 Stevia rebaudiana Species 0.000 claims description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000001143 conditioned effect Effects 0.000 claims 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims 1
- 240000007472 Leucaena leucocephala Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 35
- 241000220317 Rosa Species 0.000 abstract description 33
- 230000001105 regulatory effect Effects 0.000 abstract description 16
- 240000002853 Nelumbo nucifera Species 0.000 abstract description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 235000005686 eating Nutrition 0.000 abstract description 2
- 241000234314 Zingiber Species 0.000 description 31
- 230000005906 menstruation Effects 0.000 description 28
- 239000003814 drug Substances 0.000 description 26
- 239000000047 product Substances 0.000 description 25
- 230000036407 pain Effects 0.000 description 18
- 208000002193 Pain Diseases 0.000 description 17
- 239000008280 blood Substances 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 16
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 15
- 235000013305 food Nutrition 0.000 description 12
- 241001145025 Saussurea involucrata Species 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- CDAISMWEOUEBRE-LKPKBOIGSA-N 1D-chiro-inositol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-LKPKBOIGSA-N 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 210000001015 abdomen Anatomy 0.000 description 8
- 210000004696 endometrium Anatomy 0.000 description 8
- 229940011871 estrogen Drugs 0.000 description 8
- 239000000262 estrogen Substances 0.000 description 8
- 230000027758 ovulation cycle Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 235000019640 taste Nutrition 0.000 description 8
- 240000008886 Ceratonia siliqua Species 0.000 description 7
- 102000009151 Luteinizing Hormone Human genes 0.000 description 7
- 108010073521 Luteinizing Hormone Proteins 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 229940040129 luteinizing hormone Drugs 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 210000004291 uterus Anatomy 0.000 description 7
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 6
- 235000005979 Citrus limon Nutrition 0.000 description 6
- 244000131522 Citrus pyriformis Species 0.000 description 6
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 6
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229940028334 follicle stimulating hormone Drugs 0.000 description 6
- 210000003016 hypothalamus Anatomy 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 241000962514 Alosa chrysochloris Species 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 210000004246 corpus luteum Anatomy 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical class O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 5
- 229960000367 inositol Drugs 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 4
- 208000037093 Menstruation Disturbances Diseases 0.000 description 4
- 206010027339 Menstruation irregular Diseases 0.000 description 4
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229960001484 edetic acid Drugs 0.000 description 4
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 4
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000002175 menstrual effect Effects 0.000 description 4
- 230000003821 menstrual periods Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000016087 ovulation Effects 0.000 description 4
- 230000001817 pituitary effect Effects 0.000 description 4
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 4
- 239000000583 progesterone congener Substances 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- -1 antibacterial Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 235000021019 cranberries Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- 229930189775 mogroside Natural products 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 229960000292 pectin Drugs 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 235000021251 pulses Nutrition 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 230000001148 spastic effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- FIKFLLIUPUVONI-UHFFFAOYSA-N 8-(2-phenylethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;hydrochloride Chemical compound Cl.O1C(=O)NCC11CCN(CCC=2C=CC=CC=2)CC1 FIKFLLIUPUVONI-UHFFFAOYSA-N 0.000 description 1
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 206010006298 Breast pain Diseases 0.000 description 1
- 206010006312 Breast swelling Diseases 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000208421 Ericaceae Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 235000017367 Guainella Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 235000005206 Hibiscus Nutrition 0.000 description 1
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 description 1
- 244000284380 Hibiscus rosa sinensis Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 241000132446 Inula Species 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000006662 Mastodynia Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 235000004348 Perilla frutescens Nutrition 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 235000012511 Vaccinium Nutrition 0.000 description 1
- 241000736767 Vaccinium Species 0.000 description 1
- 244000291414 Vaccinium oxycoccus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960005164 acesulfame Drugs 0.000 description 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- VEVRNHHLCPGNDU-MUGJNUQGSA-O desmosine Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C(O)=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-O 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 235000012171 hot beverage Nutrition 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/42—Preservation of non-alcoholic beverages
- A23L2/46—Preservation of non-alcoholic beverages by heating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/62—Clouding agents; Agents to improve the cloud-stability
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/64—Re-adding volatile aromatic ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/68—Acidifying substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/70—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter
- A23L2/72—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter by filtration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Non-Alcoholic Beverages (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a beverage composition for conditioning dysmenorrheal and a production method thereof. The beverage composition for regulating dysmenorrheal comprises a snow lotus culture, carob bean extract, purple perilla, ginger, rose, cranberry concentrated powder, bonito elastin, tremella polysaccharide and the like. The beverage composition for conditioning dysmenorrhea has the advantages of obvious clinical curative effect and eating safety in the aspect of treating the dysmenorrhea of women, and is worthy of popularization and application in clinical practice for treating the dysmenorrhea of women.
Description
[ technical field ] A method for producing a semiconductor device
The invention belongs to the technical field of functional food. More particularly, the invention relates to a beverage composition for conditioning dysmenorrheal and a production method of the beverage composition for conditioning dysmenorrheal.
[ background of the invention ]
After the female enters puberty, the endometrium is affected by ovarian hormone, and periodic uterine bleeding, called menstruation, appears. The cyclic changes of the endometrium are called the menstrual cycle and are also the reproductive cycle of humans.
The interval time of the first day of two times of menstruation is more than 28-30 days, and the first day of two times of menstruation is about 7 days before or after the menstruation. The cycle length varies from person to person, but each woman must have her own regularity in the menstrual cycle, otherwise it should be considered abnormal. The menstrual cycle is regulated by the interaction between the hypothalamus, pituitary and ovary. The hypothalamus regulates the function of the pituitary, which in turn regulates the function of the ovary. The endometrium is periodically changed under the action of ovarian hormone. Sex hormones produced by the ovaries, in turn, act on the hypothalamus and pituitary gland, affecting the release, i.e., feedback, of gonadotropin-releasing hormone (Gn-RH), Follicle Stimulating Hormone (FSH), and Luteinizing Hormone (LH). When the release of the release is inhibited, negative feedback is called, and when the release of the release is promoted, positive feedback is called.
After the first menstrual cycle, corpus luteum atrophy, the secretion of estrogen and progestin decreases, releasing the depression of the hypothalamus and pituitary. The hypothalamus produces Gn-RH, which promotes secretion and release of FSH and LH. Under the synergistic action of FSH and LH, follicles in ovaries develop to mature gradually, and estrogen is produced to change the proliferative phase of endometrium. After the follicle matures, estrogen in the body rises to a first peak. The secretion of estrogen is increased, the production of FSH is inhibited, the increase of LH secretion is promoted, an LH peak appears, and ovulation is triggered. After ovulation, the corpus luteum is formed and secretes estrogen and progestogen, and under the combined action, the endometrium undergoes typical secretory phase changes. The estrogen levels temporarily decrease after ovulation, followed by a second, lower peak. The large amount of estrogen and progestogen secreted by the corpus luteum reduces the secretion of FSH and LH by the action of negative feedback, and the corpus luteum begins to shrink. Then the secretion of estrogen and progestogen is reduced, the endometrium is not supported by sex hormone, necrosis and shedding occur, and menstruation comes. After atrophy of the corpus luteum, the hypothalamus and pituitary are relieved of inhibition, and Gn-RH is re-secreted to begin another menstrual cycle.
Dysmenorrhea (dysmenorrhea) refers to the condition of lower abdominal pain, distention, soreness of the waist or other discomfort before or after menstruation or during menstruation. Pain is often spasmodic, usually located on the lower abdomen pubic bone, and can radiate to the lumbosacral area and medial thigh. The severe pain patients can have pale complexion, nausea, vomiting, cold sweating and other symptoms, and the normal life and work are seriously affected. Dysmenorrhea is one of the most common gynecological symptoms, and the incidence rate is reported in the literature to be 16.8% -81%, but the exact incidence rate is difficult to evaluate due to the difference of pain threshold values of each person and the lack of objective evaluation indexes in clinic.
The incidence rate is different in different age groups, the incidence rate is lower in the early tide, then gradually increases, the peak is reached in 16-18 years, the peak is declined in 30-35 years, the growth period is stabilized at about 40%, and the growth period is stabilized at about 20% in 50 years. Normal menses are periodic and self-limiting: the 1 st day of bleeding is the beginning of the menstrual cycle, the interval between the 1 st days of two menses is called a menstrual cycle, generally 21-35 days, and the average day is 28 days; the primary menstruation lasts for 2-8 days, the average is 4-6 days, and the normal menstruation volume is 20-60 ml. Some women experience a persistent, unpredictable advancement or retardation of menstruation, and also experience abnormal menstruation volume. Irregular menstruation, also called as menstrual disorder, is a common gynecological disease characterized by abnormal menstrual cycle, menstrual period, menstrual volume and the like, and can be accompanied by symptoms of abdominal pain, dizziness, hypodynamia and the like before and during menstruation.
Millions of patients all over the world see the dysmenorrhea and the irregular menstruation every year, which are common frequently encountered diseases in clinic, and most of the patients have repeated attacks and are decocted to seriously affect work and life.
Dysmenorrhea is classified into primary dysmenorrhea and secondary dysmenorrhea. Primary dysmenorrhea, i.e. functional dysmenorrhea, refers to menstrual pain, which is usually spastic and concentrated in the lower abdomen. Other symptoms include headache, hypodynamia, dizziness, nausea, vomiting, diarrhea, lumbago and skelalgia, which are often seen in young women, and primary dysmenorrhea is not accompanied by obvious pelvic organic diseases. Secondary dysmenorrhea refers to the condition of marked pathological changes of reproductive organs, such as endometriosis, pelvic inflammatory disease, tumor, etc.
For primary dysmenorrhea, the dietary habit of patients needs to be changed, and the patients need not to eat uncooked and cold stimulating food, and avoid inducing or aggravating pain. When in dysmenorrhea, the lower abdomen can be laid in bed or hot compressed, and infrared physiotherapy is performed, and the personal hygiene in menstrual period is noticed, so as to improve and relieve the symptoms of dysmenorrhea.
At present, non-steroidal anti-inflammatory drugs (ibuprofen, phenylbutazone, oxyphenbutazone) and other drugs are mostly adopted to treat dysmenorrhea in modern medicine, but although the drugs have obvious effect of immediately relieving dysmenorrhea, the drugs can cause gastrointestinal tract, dizziness, toxic and side effects of liver and kidney, endocrine disorders and other adverse reactions after being taken for a long time.
The traditional Chinese medicine considers that the primary dysmenorrhea belongs to the categories of abdominal pain during menstruation and dysmenorrhea of virgin women in the traditional Chinese medicine. Although clinically, primary dysmenorrhea is characterized by qi stagnation and blood stasis, damp-heat stagnation, qi and blood deficiency, liver and kidney deficiency, it is mostly cold-damp stagnation. Blood congeals when cold, and moves when hot, and cold drinks during menstrual period or rain and water are produced, cold dampness can invade thoroughfare and conception vessels and uterus for a long time, so that blood coagulation is unsmooth, blood stagnation is not moved, and pain is remained. The treatment should be channel warming, cold dispelling, dampness eliminating, blood stasis removing, qi circulation promoting, and blood circulation promoting.
However, most of the traditional Chinese medicine compositions for treating dysmenorrhea in the prior art are prepared from a plurality of raw materials, have poor taste and poor effect, so that the inventor of the invention finally completes the invention by summarizing the prior art and a large amount of experimental research and analysis on the basis of summarizing the prior art.
[ summary of the invention ]
[ problem to be solved ]
The invention aims to provide a drink composition for conditioning dysmenorrheal.
Another object of the present invention is to provide a method for producing the beverage composition for conditioning dysmenorrhea.
[ solution ]
The invention is realized by the following technical scheme.
The invention relates to a beverage composition for conditioning dysmenorrheal.
The beverage composition for conditioning dysmenorrheal contains the following components: in parts by weight
According to a preferred embodiment of the invention, the beverage composition for conditioning dysmenorrheal comprises the following components: in parts by weight
According to another preferred embodiment of the invention, the beverage composition for conditioning dysmenorrheal comprises the following components: in parts by weight
According to another preferred embodiment of the invention, the beverage composition for conditioning dysmenorrheal contains 0.02-2.0 parts by weight of stabilizer.
According to another preferred embodiment of the present invention, the stabilizer is one or more stabilizers selected from pectin, xanthan gum, EDTA, CMC-Na, guar gum, sodium alginate, β -cyclodextrin, calcium alginate, gum arabic, gelatin, agar or cyclodextrin.
According to another preferred embodiment of the invention, the beverage composition for conditioning dysmenorrheal contains 0.25-25.0 parts by weight of sweetener.
According to another preferred embodiment of the present invention, the sweetener is one or more selected from the group consisting of white granulated sugar, erythritol, xylitol, isomalt, isomaltooligosaccharide, sucralose, acesulfame potassium, stevia, and glycyrrhizin.
According to another preferred embodiment of the invention, the beverage composition for conditioning dysmenorrheal contains 0.0015-0.15 part by weight of an acid-base regulator.
According to another preferred embodiment of the present invention, the pH regulator is one or more pH regulators selected from malic acid, citric acid, sodium citrate, lactic acid and fumaric acid.
The invention relates to a production method of a beverage composition for conditioning dysmenorrheal.
The production method comprises the following production steps:
A) adding 0.02-80.0 parts by weight of saussurea involucrate culture, 0.05-5.0 parts by weight of ginger slices and 0.3-10.0 parts by weight of purple perilla into an extraction tank, and soaking in water for 25-35 minutes;
B) heating and boiling the soaked substance in the step A, preserving heat for 12-18 minutes, adding 0.01-6.0 parts by weight of double-petal roses, and preserving heat for 12-18 minutes; then filtering with a sand rod filter, pumping the filtrate into an extract storage tank, and heating to 60 ℃;
C) adding 0.0015-0.15 part by weight of an acid-base regulator, 0.01-1.0 part by weight of cranberry concentrated powder and 0.025-2.5 parts by weight of carob bean extract into the extracting solution obtained in the step B, and stirring for dissolving;
D) uniformly mixing 0.02-2.0 parts by weight of a stabilizer, 0.00015-0.015 part by weight of bonito elastin peptide, 0.00015-0.015 part by weight of tremella polysaccharide and a sweetening agent, adding the mixture into the solution obtained in the step C, and stirring and dissolving the mixture; adding a sweetening agent to enable the total amount of the sweetening agent to reach 0.25-25.0 parts by weight, stirring and heating to 80 ℃, and keeping the temperature for 8-12 minutes;
E) adding 0.00165-0.165 parts of edible essence, stirring uniformly, and then adding water to the total amount of 100 parts by weight; cooling to 45 ℃, filtering by a plate-and-frame filter, and sterilizing the obtained filtrate at 115 ℃ for 20 minutes to obtain the dysmenorrheal conditioning beverage composition;
or sterilizing the obtained filtrate by using an ultrahigh-temperature instant sterilizer, filling the sterilized filtrate into a clean glass bottle, sealing the cover, spraying the sterilized filtrate by a conveyor belt through a spray cooler, spraying the sterilized filtrate by hot water at 80-90 ℃ and cooling the sterilized filtrate by warm water at 25-40 ℃ to obtain the dysmenorrheal-conditioning beverage composition.
The present invention will be described in more detail below.
The invention relates to a beverage composition for conditioning dysmenorrheal.
The beverage composition for conditioning dysmenorrheal contains the following components: in parts by weight
The saussurea involucrate is a unique rare or endangered medicinal plant in China, is the only saussurea involucrate variety listed as Chinese pharmacopoeia, and has the reputation of 'king of hundred herbs and best quality in medicine' from ancient times. According to records in the Chinese pharmacopoeia, the wine is warm and slightly bitter in taste, enters three channels of liver, spleen and kidney, and has the effects of promoting blood circulation, removing obstruction in collaterals, dispelling cold, removing dampness, strengthening tendons, tonifying yang and the like. The classic "Taoism preservation" of Taoisseur between the first 1300 years of the Tang Dynasty and the first three years of the Yuan shan saussurea is known as one of the "Jiu Da Xiancao of China". Tianshan saussurea involucrata is recorded in Tibetan medicine documents Yue Wang Yazhen and Si Shi Dian: the Han nationality is regarded as a treasure for improving the rheumatoid arthritis, and the Uygur and Kazak nationality are regarded as good gynecological medicines; in the Yan from Sichuan Zhi Yao Zhi, it can clear cold, resolve phlegm and water retention, strengthen yang, enrich blood and warm uterus. For treating male impotence, female menoxenia, metrorrhagia, metrostaxis and leukorrhagia; the book of Xinjiang Chinese herbal medicine says that the book can promote menstruation, activate blood, strengthen tendons and bones and promote uterine contraction. It can be used for treating rheumatic arthritis, female abdominal psychroalgia, amenorrhea, retained afterbirth, measles without adequate eruption, cough due to lung cold, and sexual impotence.
In 2010, saussurea involucrate cultures were approved as new resource foods of medicinal plant cell type, and the specifications of the saussurea involucrate cultures are shown in table 1.
TABLE 1 New resources food Specifications
| Fresh saussurea involucrata culture | Dried saussurea involucrata culture | |
| Traits | Purple red bulk particle | Purple gray powder |
| Protein | ≥1％ | ≥20％ |
| Total Flavonoids | ≥0.4％ | ≥7％ |
| Moisture content | ≤96％ | ≤10％ |
| Ash content | ≤1％ | ≤10％ |
| Amount of food consumed | Less than or equal to 80 g/day | Less than or equal to 4 g/day |
The saussurea involucrata culture is a cell product which is obtained by screening the best wild saussurea involucrata seed source, applying an advanced cell culture technology and under the strictly controlled culture condition, obtaining the saussurea involucrata cells with the best living environment and sufficient nutrition, and simultaneously carrying out screening, detection, identification, culture and re-screening for thousands of times, and the cell product is referred to the document ' Ministry of health, Ministry of health ' for approving 5 articles such as golden camellia, inula flower (small black drug) and the like as new resource food, the Ministry of health ' bulletin No. 9 of 2010.
The research result of the efficacy of the saussurea involucrate culture shows that: the traditional Chinese medicine composition has the effects of resisting fatigue, rheumatism, inflammation and pain, regulating blood fat, resisting oxidation, enhancing immunity, resisting radiation, enhancing bone density, resisting ultraviolet absorption, resisting bacteria, promoting blood circulation, removing blood stasis, resisting inflammation, inhibiting tumor cells in a broad spectrum, resisting oxidation, removing free radicals, inhibiting melanin generation and resisting saccharification, and is disclosed in the document Liuya duckweed-saussurea involucrata culture main efficacy research, Chinese traditional medicine basic medicine journal 2010,16(10): 929-.
According to the invention, the main effect of the saussurea involucrate culture in the beverage composition for conditioning dysmenorrheal is warming uterus and replenishing blood.
The saussurea involucrate culture used in the present invention is a product currently marketed, for example, saussurea involucrate culture sold under the trade name proeka by the company Dalipekang biotech Limited.
The carob bean extract is an extract obtained by extracting carob pod carob bean.
The pod of the carob tree is an elongated pod which has a peculiar phenomenon, that is, wherever it grows, it forms seeds each of which has a uniform weight and a mass of about 0.197 g. Modern research has shown that carob contains a high content of vitamins and minerals, in particular D-chiro-inositol (DCI). D-chiro-inositol belongs to vitamin B group, is one of nine isomers of inositol with optical rotation, and is an inositol substance which is widely researched in recent years.
In the last 90 s of the century, scientists found that patients with hyperglycemia had low concentrations of D-chiro-inositol in the stools and subsequently found that such patients had low concentrations in the urine, muscle, and hemodialysis. The field of research on female health began in the end of the 90 s, when D-chiro-inositol was found to increase ovulation in women with polycystic ovary syndrome (PCOS), researchers developed studies on the molecular structure and extraction process thereof, and gradually achieved industrialization by extracting active substances from carob shells by an enzyme treatment method at the initial stage of the study. Actually, DCI active ingredients naturally exist in Chinese people, but the DCI active ingredients are not abundant in food and are scarce food ingredients, so that the body must convert the chiral inositol from myoinositol. Although myo-inositol is abundant in many foods, conversion is a very complex process. Many people, especially people with irregular menstruation, do not convert myo-inositol manuum (DCI) well in their body. Experiments show that the extract of carob, which is rich in DCI, has the following significant health benefits: 1) regulating the physiological cycle; 2) ameliorating polycystic ovary syndrome (PCOS); 3) improving metabolic syndrome; 4) aid pregnancy and prevent gestational diabetes.
According to the present invention, the main effect of carob bean extract in the beverage composition for regulating dysmenorrhea of the present invention is to regulate menstrual physiological cycle.
The carob bean extract used in the present invention is a product currently marketed, such as the carob bean extract distributed by Shanghai honesty, a major health group company, manufactured by American company, Inc., Korea.
Perilla frutescens, perilla leaf in traditional medicine, has the effects of depressing qi, reducing phlegm, relieving cough and asthma, relieving exterior syndrome and dispelling cold, regulating qi to alleviate pain, relaxing bowel and detoxifying, and modern pharmacology considers that the perilla leaf has various biological activities, such as anti-inflammatory, antioxidant, antibacterial, antidepressant, antitumor, sedative and the like. Perilla stem is warm in nature and pungent in taste, enters lung and spleen channels, has effects of regulating qi-flowing, relieving epigastric distention, relieving pain, and preventing miscarriage, and can be used for treating chest distress, epigastric pain, belch, emesis, and threatened abortion. Modern medicine proves that perilla stem has stronger activities of oxidation resistance, inflammation resistance, bacteria resistance, virus resistance, tumor resistance and the like.
According to the invention, the main effect of the perilla in the drink composition for conditioning dysmenorrheal is uterus calming and pain relieving.
The perilla used in the invention is perilla leaf or stem, which is a product sold in the current market, such as perilla sold by Anhui gold hibiscus Chinese medicinal decoction pieces Limited.
Ginger, rhizoma Zingiberis recens is warm in nature, and has the effects of relieving exterior syndrome, dredging collaterals, warming middle-jiao and dispelling cold.
According to the invention, the main effect of ginger in the drink composition for conditioning dysmenorrheal is to warm the middle-jiao and dispel cold.
The ginger used in the present invention is a product currently marketed, for example, ginger sold by the Wuxi mustard vegetable Co.
The rose has the functions of regulating qi, promoting blood circulation, astringing and the like, is mainly used for treating irregular menstruation, traumatic injury, liver qi and stomach pain, breast swelling and pain and other symptoms, and modern medicine proves that the rose with double petals has the functions of resisting oxidation, resisting aging, resisting bacteria, resisting allergy, whitening and resisting inflammation.
According to the invention, the major effect of the rose with double petals in the drink composition for regulating dysmenorrhea is to regulate qi, activate blood and astringe.
The rose with double petals used in the invention is a product sold in the market at present, for example, the rose with double petals sold by Jinan Tianyuan Rose product development Limited company.
Cranberries, also known as cranberries, are plants of the genus Vaccinium of the family Ericaceae, grown in wetlands and sandy soils ranging from warm to cold in the northern hemisphere, and are currently grown primarily in the eastern and northeastern United states and in most regions of Canada. The cranberry is an oval berry with the length of 2-5cm, the pulp under the red skin is from white to deep red, and the cranberry tastes sour and slightly sweet. The cranberry is a precious resource of nutrient substances such as cellulose, organic acid and polyphenol, has multiple functions of maintaining human digestive health, resisting oxidation and the like, and is popular among consumers. The cranberry concentrated powder has antioxidant property, and has the functions of resisting tumor, preventing cardiovascular diseases, delaying aging, etc. The research also finds that the bioactive components of the cranberry have antibacterial capacity. Cranberry can be used for preventing Urinary Tract Infection (UTI) by preventing bacterial infection of urinary system.
According to the invention, the main effect of the cranberry concentrated powder in the drink composition for conditioning dysmenorrheal is antibiosis and antiphlogosis.
The cranberry concentrated flour used in the present invention is a product currently marketed, for example, cranberry concentrated flour marketed by beijing jiakang nutrition technologies ltd.
The bonito elastin is derived from bonito heart artery, contains specific amino acids such as desmosine, isodesmosine and little hydroxy-proline, and has effects of activating more skin fibroblast, promoting collagen production, increasing skin elasticity, increasing skin average blood flow, and accelerating endometrium healing.
According to the present invention, the main effect of bonito elastin in the composition for regulating dysmenorrhea drink of the present invention is to accelerate the healing after endometrial prolapse.
The bonito elastin used in the present invention is a product currently sold in the market, such as bonito elastin manufactured by JAPAN BIO SCIENCE LABORATORY co, LTD, distributed by shanghai cheng a major health SCIENCE LTD.
Tremella is a traditional beauty nourishing product in China and is a rare edible fungus recognized in the world. The tremella polysaccharide is a main active component of a tremella extract, takes mannose as a main chain, and contains acidic mucopolysaccharide of xylose, fucose and glucuronic acid on side chains; the tremella polysaccharide water solution is colorless, odorless, transparent and very high in viscosity, and can endow products with unusual soft and smooth mouthfeel. The Tremella polysaccharide has biological response regulating effect, can be used as immunomodulator and antiallergic agent, and can stimulate activity of immunocyte, enhance phagocytosis of tumor cell, activate T cell and B cell, and promote formation of antibody.
According to the invention, the main effect of the tremella polysaccharide in the beverage composition for conditioning dysmenorrhea is to increase the immunity during menstruation.
The tremella polysaccharide used in the present invention is a product currently marketed, such as that sold by Shanghai Chenghui-a major health technology Co., Ltd, produced by Shanghai Huiwen Biotechnology Ltd.
According to the present invention, the main role of the edible essence in the beverage composition for conditioning dysmenorrhea is to regulate the odor of the beverage.
The edible essences used in the present invention are cranberry essence, rose essence, and lemon essence, which are products currently sold in the market, such as cranberry essence sold by Guangzhou Kai essence perfumery Co., Ltd, rose essence sold by forest essence pigment technology (China) Co., Ltd, and lemon essence sold by Hongtai Biotechnology Co., Ltd, Zhuhai City.
According to the present invention, when the contents of carob bean extract, perilla, ginger, rose, cranberry concentrated powder, bonito elastin, tremella polysaccharide and edible essence are within the above range, if the content of the saussurea involucrate culture is less than 0.02 parts by weight, the effect is insignificant; if the content of the saussurea involucrate culture is higher than 80.0 parts by weight, the new resource food is not met; therefore, the content of the saussurea involucrate culture is suitably 0.02 to 80.0 parts by weight, preferably 0.12 to 50.0 parts by weight, more preferably 1.50 to 30.0 parts by weight;
similarly, when the contents of the saussurea involucrate culture, the perilla, the ginger, the rose with double petals, the cranberry concentrated powder, the bonito elastin, the tremella polysaccharide and the edible essence are within the range, if the content of the carob extract is less than 0.025 parts by weight, the effect is not significant; if the content of the carob bean extract is more than 2.5 parts by weight, the taste of the beverage is not good; therefore, it is reasonable that the content of the carob bean extract is 0.025 to 2.5 parts by weight, preferably 0.25 to 2.0 parts by weight, more preferably 0.65 to 1.6 parts by weight;
when the contents of the saussurea involucrate culture, the carob bean extract, the ginger, the rose, the cranberry concentrated powder, the bonito elastin, the tremella polysaccharide and the edible essence are in the range, if the content of the purple perilla is lower than 0.3 part by weight, the effect is not obvious; if the content of the perilla is higher than 10.0 parts by weight, the content exceeds the specification (5-10 g) of pharmacopeia usage and dosage; therefore, the content of the perilla is suitably 0.3 to 10.0 parts by weight, preferably 3.0 to 8.0 parts by weight, more preferably 4.0 to 7.0 parts by weight;
when the contents of the saussurea involucrate culture, the carob bean extract, the perilla, the double-petal rose, the cranberry concentrated powder, the bonito elastin, the tremella polysaccharide and the edible essence are in the range, if the content of the ginger is lower than 0.05 part by weight, the effect is not obvious; if the content of ginger is more than 5.0 parts by weight, the taste of the beverage is not good; therefore, the content of ginger is preferably 0.05 to 5.0 parts by weight, preferably 0.5 to 3.8 parts by weight, more preferably 1.2 to 3.0 parts by weight;
when the contents of the saussurea involucrate culture, the carob bean extract, the perilla, the ginger, the cranberry concentrated powder, the bonito elastin, the tremella polysaccharide and the edible essence are in the range, if the content of the double-petal rose is less than 0.01 part by weight, the effect is not obvious; if the content of the rose with the double petals is higher than 6.0 parts by weight, the dosage is more than the pharmacopeia usage and dosage regulation (3-6 g); therefore, the content of the rose with the double petals is feasible to be 0.01 to 6.0 parts by weight, preferably 0.06 to 4.82 parts by weight, and more preferably 0.12 to 3.60 parts by weight;
when the contents of the saussurea involucrate culture, the carob bean extract, the perilla, the ginger, the rose with double petals, the bonito elastin, the tremella polysaccharide and the edible essence are in the range, if the content of the cranberry concentrated powder is lower than 0.01 part by weight, the effect is not obvious; if the content of the cranberry concentrated powder is higher than 1.0 part by weight, the beverage is precipitated too much; thus, it is feasible that the cranberry concentrate flour is present in an amount of 0.01 to 1.0 parts by weight, preferably 0.05 to 0.86 parts by weight, more preferably 0.15 to 0.66 parts by weight;
when the contents of the saussurea involucrata culture, the carob bean extract, the perilla, the ginger, the rose with double petals, the cranberry concentrated powder, the tremella polysaccharide and the edible essence are in the range, if the content of the skipjack elastin is lower than 0.00015 part by weight, the effect is not obvious; if the content of the skipjack elastin is higher than 0.015 weight parts, the cost of the beverage is too high; therefore, the content of the skipjack elastin is preferably 0.00015 to 0.015 parts by weight, more preferably 0.0015 to 0.014 parts by weight, and still more preferably 0.0042 to 0.012 parts by weight;
when the contents of the saussurea involucrate culture, the carob bean extract, the perilla, the ginger, the rose with double petals, the cranberry concentrated powder, the bonito elastin and the edible essence are in the range, if the content of the tremella polysaccharide is lower than 0.00015 part by weight, the effect is not obvious; if the content of the tremella polysaccharide is higher than 0.015 weight part, the beverage has poor sense; therefore, the content of the tremella polysaccharide is suitably 0.00015 to 0.015 parts by weight, preferably 0.0015 to 0.014 parts by weight, more preferably 0.0035 to 0.012 parts by weight;
when the contents of the saussurea involucrate culture, the carob bean extract, the perilla, the ginger, the rose with double petals, the cranberry concentrated powder, the bonito elastin and the tremella polysaccharide are in the range, if the content of the edible essence exceeds the range, the edible essence is not desirable, and a consumer thinks that the product is prepared by blending the essence because the edible essence is too much.
Preferably, the beverage composition for conditioning dysmenorrheal contains the following components: in parts by weight
More preferably, the beverage composition for conditioning dysmenorrheal contains the following components: in parts by weight
According to the invention, the beverage composition for conditioning dysmenorrheal further comprises 0.02-2.0 parts by weight of a stabilizer.
The stabilizer has the main function of forming a uniform and stable suspension liquid in the beverage composition for conditioning dysmenorrheal.
In the present invention, any other stabilizer having the above-mentioned effects and having no negative influence on the performance of the composition for treating dysmenorrhea and the application thereof can be used in the present invention, and they are also within the scope of the present invention.
According to the present invention, if the content of the stabilizer is less than 0.02 parts by weight, the stabilizing effect is not significant; if the content of the stabilizer is more than 2.0 parts by weight, the flowability of the beverage is poor; therefore, the content of the stabilizer is preferably 0.02 to 2.0 parts by weight;
the stabilizer used in the present invention is one or more stabilizers selected from the group consisting of pectin, xanthan gum, EDTA (ethylene diamine tetraacetic acid), CMC-Na (sodium carboxymethylcellulose), guar gum, sodium alginate, beta-cyclodextrin, calcium alginate, gum arabic, gelatin, agar, which are all currently marketed products such as pectin sold by Shanghai Haoye food science Co., Ltd, guar gum sold by Guangzhou Kale Bio Co., Ltd, beta-cyclodextrin sold by Mengzhou Huaxing Biochemical Co., Ltd, xanthan gum sold by Shandong Jingyun food ingredient Co., Ltd, sodium alginate sold by Xuzhou Fengrui Biotech Co., Ltd, calcium alginate, agar sold by Hebei Source Biotech Co., Ltd, CMC-Na sold by Yilong Bio Co., Ltd, gum arabic, EDTA sold by Shandong Jianchuan Biotech Co., Ltd, gelatin sold by new changteng food of anhui limited.
According to the invention, the beverage composition for conditioning dysmenorrheal contains 0.25-25.0 parts by weight of sweetening agent.
The main function of the sweetener in the beverage composition for conditioning dysmenorrheal is to adjust the sweetness of the beverage, and the beverage composition is easy to take.
In the present invention, any other sweetener having the above-mentioned effects and not adversely affecting the performance of the composition for conditioning dysmenorrhea and the use thereof according to the present invention can be used in the present invention, and they are also within the scope of the present invention.
According to the present invention, if the content of the sweetener is less than 0.25 parts by weight, there is no sweetness; if the content of the sweetener is higher than 25.0 parts by weight, the sweetener is excessively sweet; therefore, the content of the sweetener is suitably 0.25 to 25.0 parts by weight;
the sweetener used in the invention is one or more selected from white granulated sugar, erythritol, xylitol, isomalt, isomaltose hypgather, sucralose, acesulfame potassium, stevioside, glycyrrhizin and mogroside, which are products sold in the market at present, for example, white sugar sold by Nanning sugar industry Co., Ltd, erythritol sold by Baobao Bio-resources Co., Ltd, xylitol sold by Zhejiang Huakang pharmaceutical industry Co., Ltd, isomalt sold by Shandong Lvjian Life Biotechnology Co., Ltd, isomaltooligosaccharide sold by Baobao Bio-resources Co., Ltd, sucralose, stevioside, mogroside sold by Qianji Bio-engineering Co., Ltd, acesulfame sold by Qianji Bio-technology Co., Ltd, glycyrrhizin sold by Shandong kang Bio-technology Co., Ltd.
According to the invention, the beverage composition for conditioning dysmenorrheal contains 0.0015-0.15 part by weight of an acid-base regulator.
The main effect of the acid-base regulator in the beverage composition for conditioning dysmenorrheal is to regulate the acidity of the beverage, and the beverage composition is easy to take.
In the present invention, any other acid-base regulator which has the above-mentioned effects and does not have negative influence on the performance of the composition for regulating dysmenorrhea and the application thereof can be used in the present invention, and the acid-base regulator are also within the protection scope of the present invention.
According to the present invention, if the content of the acid-base modifier is less than 0.0015 parts by weight, the degree of sourness and sweetness is not good; peracid if the content of the pH regulator is more than 0.15 parts by weight; therefore, the content of the acid-base regulator is proper to be 0.0015-0.15 weight part;
the pH adjustor used in the present invention is one or more pH adjustor selected from malic acid, citric acid, sodium citrate, lactic acid or fumaric acid, which are currently commercially available products such as malic acid sold by Suzhou Minny accurate nutrition science Co., Ltd, citric acid sold by Weifang Yingxuan industry Co., Ltd, sodium citrate, lactic acid sold by Henan Jindan lactic acid science Co., Ltd, fumaric acid sold by Anhui Xue Bioscience Co., Ltd.
The invention relates to a production method of a beverage composition for conditioning dysmenorrheal.
The production method comprises the following production steps:
A) adding 0.02-80.0 parts by weight of saussurea involucrate culture, 0.05-5.0 parts by weight of ginger slices and 0.3-10.0 parts by weight of purple perilla into an extraction tank, and soaking in water for 25-35 minutes;
B) heating and boiling the soaked substance in the step A, preserving heat for 12-18 minutes, adding 0.01-6.0 parts by weight of double-petal roses, and preserving heat for 12-18 minutes; then filtering with a sand rod filter, pumping the filtrate into an extract storage tank, and heating to 60 ℃;
C) adding 0.0015-0.15 part by weight of an acid-base regulator, 0.01-1.0 part by weight of cranberry concentrated powder and 0.025-2.5 parts by weight of carob bean extract into the extracting solution obtained in the step B, and stirring for dissolving;
D) uniformly mixing 0.02-2.0 parts by weight of a stabilizer, 0.00015-0.015 part by weight of bonito elastin peptide, 0.00015-0.015 part by weight of tremella polysaccharide and a sweetening agent, adding the mixture into the solution obtained in the step C, and stirring and dissolving the mixture; adding a sweetening agent to enable the total amount of the sweetening agent to reach 0.25-25.0 parts by weight, stirring and heating to 80 ℃, and keeping the temperature for 8-12 minutes;
E) adding 0.00165-0.165 parts of edible essence, stirring uniformly, and then adding water to the total amount of 100 parts by weight; cooling to 45 ℃, filtering by a plate-and-frame filter, and sterilizing the obtained filtrate at 115 ℃ for 20 minutes to obtain the dysmenorrheal conditioning beverage composition.
The conditions of the saussurea involucrate culture, carob bean extract, perilla, ginger, rose, cranberry concentrated powder, bonito elastin, tremella polysaccharide, edible essence, stabilizer, sweetener and acid-base regulator have been described above, and thus are not described herein again.
Or in the step E, sterilizing the obtained filtrate by using an ultrahigh-temperature instant sterilizer, filling the sterilized filtrate into a clean glass bottle, sealing the cover, spraying the sterilized filtrate by a conveyor belt through a spray cooler, spraying the sterilized filtrate by hot water at 80-90 ℃ and cooling the sterilized filtrate by warm water at 25-40 ℃ to obtain the dysmenorrheal conditioning beverage composition.
The extraction tank, the sand rod filter, the plate frame filter and the sterilization equipment used in the production method are all products sold in the current market, such as the extraction tank sold by Yixin pharmaceutical equipment Limited company under the trade name of Huale brand, the sand rod filter sold by Yixing pharmaceutical machinery factory company, the plate frame filter sold by Ningbo Yongquan pharmaceutical Limited company under the model number CXAS-1, and the ultra-high temperature instant sterilizer sold by Taiji stone (Shanghai) engineering technology Limited company;
the conditioning dysmenorrheal drink composition produced by the production method has the following characteristics according to the detection of the GB/T31326 standard method:
brownish red, slightly sweet in taste, and has the special taste and smell of saussurea involucrata and rose.
Nutrient composition table
| Item | Per 100mL | NRV％ |
| (Energy) | 17～595kJ | 0～7％ |
| Protein | 0 | 0 |
| Fat | 0 | 0 |
| Carbohydrate compound | 1～35g | 0～10％ |
| Sodium salt | 6～600mg | 0～30％ |
[ advantageous effects ]
The beverage composition for regulating dysmenorrheal is a beverage containing components such as saussurea involucrata culture, carob bean extract, purple perilla, ginger, rose with double petals, cranberry concentrated powder, bonito elastin, tremella polysaccharide and the like. The beverage composition for regulating dysmenorrheal can act on regulating organs 'ovary' of female menstruation, generation organs 'uterus' of the menstruation and excretion organs 'vagina' of the menstruation, saussurea involucrate culture warms uterus and enriches blood, carob bean extract regulates menstrual physiological cycle, perilla is used for calming uterus and relieving pain, ginger is used for warming middle-jiao and dispelling cold, rose is used for regulating qi, promoting blood circulation and astringing, cranberry concentrated powder is used for resisting bacteria and diminishing inflammation, bonito elastin is used for accelerating endometrium healing, and tremella polysaccharide is used for improving immunity of female menstruation. The invention combines eight foods with food homology, has synergistic effect, and has the function of obviously improving the dysmenorrhea as proved by human functional experiments.
[ detailed description ] embodiments
The invention will be better understood from the following examples.
Example 1: the beverage composition for conditioning dysmenorrheal
The beverage composition for conditioning dysmenorrheal comprises the following components:
1.0 part by weight of saussurea involucrate culture, 0.025 part by weight of carob bean extract, 1.8 parts by weight of perilla, 0.12 part by weight of ginger, 0.10 part by weight of rose, 0.8 part by weight of cranberry concentrated powder, 0.0042 part by weight of bonito elastin, 0.0018 part by weight of tremella polysaccharide, 0.002 part by weight of cranberry essence sold by Kyowa essence perfume company, 0.1 part by weight of stabilizer, 0.95 part by weight of white granulated sugar sweetener sold by Nanning sugar industry Co., Ltd, 0.0086 part by weight of malic acid-base regulator sold by Suzhou Minni precision nutrition technology Co., Ltd, and water to make up to a total amount of 100 parts by weight.
The beverage composition for conditioning dysmenorrheal is produced by the following production steps:
A) adding 1.0 weight part of saussurea involucrate culture, 0.12 weight part of ginger slices and 1.8 weight parts of purple perilla into an extraction tank, and soaking in water for 25 minutes;
B) heating and boiling the soaked substance in the step A, keeping the temperature for 12 minutes, adding 0.10 part by weight of double-petal roses, and keeping the temperature for 12 minutes; then filtering with a sand rod filter, pumping the filtrate into an extract storage tank, and heating to 60 ℃;
C) adding 0.0086 weight part of malic acid-base regulator, 0.8 weight part of cranberry concentrated powder and 0.025 weight part of carob bean extract into the extracting solution obtained in the step B, and stirring for dissolving;
D) uniformly mixing 0.0042 parts by weight of skipjack elastin peptide, 0.0018 parts by weight of tremella polysaccharide and white granulated sugar sweetener, adding the mixture into the solution obtained in the step C, and stirring for dissolving; then adding a white granulated sugar sweetener to enable the total amount of the sweetener to reach 0.95 weight part, stirring and heating to 80 ℃, and keeping the temperature for 8 minutes;
E) adding 0.002 weight part of cranberry essence, uniformly stirring, and then adding water until the total weight is 100 weight parts; cooling to 45 ℃, filtering by a plate-and-frame filter, placing the obtained filtrate in a sterilization cabinet, and sterilizing at the temperature of 115 ℃ for 20 minutes to obtain the dysmenorrheal conditioning beverage composition.
Example 2: the beverage composition for conditioning dysmenorrheal
The beverage composition for conditioning dysmenorrheal comprises the following components:
10.0 parts by weight of a snow lotus culture, 0.10 parts by weight of a carob bean extract, 10.0 parts by weight of perilla, 0.84 parts by weight of ginger, 0.4 parts by weight of heavy petal rose, 1.0 parts by weight of cranberry concentrated powder, 0.0098 parts by weight of bonito elastin, 0.0046 parts by weight of tremella polysaccharide, 0.005 parts by weight of rose essence sold by sennin essence technology (china) limited, 0.02 parts by weight of a xanthan gum stabilizer sold by shandong Jingyun food ingredients limited, 5.2 parts by weight of white granulated sugar sweetener sold by Nanning sugar industries, 0.012 parts by weight of a malic acid regulator sold by Suzhou Minni accurate nutrition technology limited, and water to a total amount of 100 parts by weight.
The beverage composition for conditioning dysmenorrheal is produced by the following production steps:
A) adding 10.0 parts by weight of saussurea involucrate culture, 0.84 parts by weight of ginger slices and 10.0 parts by weight of purple perilla into an extraction tank, and soaking in water for 35 minutes;
B) heating and boiling the soaked substance in the step A, preserving heat for 15 minutes, adding 0.4 part by weight of double-petal roses, and preserving heat for 15 minutes; then filtering with a sand rod filter, pumping the filtrate into an extract storage tank, and heating to 60 ℃;
C) adding 1.0 part by weight of cranberry concentrated powder and 0.10 part by weight of carob bean extract into the extracting solution obtained in the step B, and stirring for dissolving;
D) uniformly mixing 0.02 part by weight of xanthan gum stabilizer, 0.0098 part by weight of skipjack elastin peptide, 0.0046 part by weight of tremella polysaccharide and white granulated sugar sweetener, adding into the solution obtained in the step C, and stirring for dissolving; then adding a white granulated sugar sweetener to ensure that the total amount of the sweetener reaches 5.2 parts by weight, stirring and heating to 80 ℃, and keeping the temperature for 12 minutes;
E) adding 0.005 part by weight of rose essence, stirring uniformly, and then adding water until the total amount is 100 parts by weight; cooling to 45 ℃, filtering by a plate-and-frame filter, placing the obtained filtrate in a sterilization cabinet, and sterilizing at the temperature of 115 ℃ for 20 minutes to obtain the dysmenorrheal conditioning beverage composition.
Example 3: the beverage composition for conditioning dysmenorrheal
The beverage composition for conditioning dysmenorrheal comprises the following components:
45.0 parts by weight of saussurea involucrate culture, 1.8 parts by weight of carob bean extract, 0.3 part by weight of perilla, 0.05 part by weight of ginger, 0.01 part by weight of rose, 0.01 part by weight of cranberry concentrated powder, 0.00015 part by weight of bonito elastin, 0.00015 part by weight of tremella polysaccharide, 0.015 part by weight of lemon essence sold by Hongtai biotechnology limited of Zhuhai city, 0.10 part by weight of sodium alginate stabilizer sold by Xuzhou Fengrui biotechnology limited, 16.8 parts by weight of xylitol sweetener sold by Zhejiang Huakang medicine industry limited, 0.0015 part by weight of sodium citrate regulator sold by Weifang Xuanying industry limited, and water to make up to a total amount of 100 parts by weight.
The beverage composition for conditioning dysmenorrheal is produced by the following production steps:
A) adding 45.0 parts by weight of saussurea involucrate culture, 0.05 parts by weight of ginger slices and 0.3 parts by weight of purple perilla into an extraction tank, and soaking in water for 30 minutes;
B) heating and boiling the soaked substance in the step A, preserving heat for 18 minutes, adding 0.01 part by weight of double-petal roses, and preserving heat for 18 minutes; then filtering with a sand rod filter, pumping the filtrate into an extract storage tank, and heating to 60 ℃;
C) adding 0.0015 part by weight of sodium citrate acid-base regulator, 0.01 part by weight of cranberry concentrated powder and 1.8 parts by weight of carob bean extract into the extracting solution obtained in the step B, and stirring for dissolving;
D) uniformly mixing 0.10 part by weight of sodium alginate stabilizer, 0.00015 part by weight of bonito elastin peptide, 0.00015 part by weight of tremella polysaccharide and xylitol sweetener, adding into the solution obtained in the step C, and stirring for dissolving; adding xylitol sweetener to make the total amount of the sweetener reach 16.8 parts by weight, stirring and heating to 80 ℃, and keeping the temperature for 12 minutes;
E) adding 0.015 weight part of lemon essence, uniformly stirring, and then adding water until the total amount is 100 weight parts; cooling to 45 ℃, filtering by a plate-and-frame filter, placing the obtained filtrate in a sterilization cabinet, and sterilizing at the temperature of 115 ℃ for 20 minutes to obtain the dysmenorrheal conditioning beverage composition.
Example 4: the beverage composition for conditioning dysmenorrheal
The beverage composition for conditioning dysmenorrheal comprises the following components:
80.0 parts by weight of saussurea involucrata culture, 2.5 parts by weight of carob bean extract, 0.9 parts by weight of perilla, 1.65 parts by weight of ginger, 0.06 parts by weight of rose, 0.05 parts by weight of cranberry concentrated powder, 0.00065 parts by weight of bonito elastin, 0.00075 parts by weight of tremella polysaccharide, 0.025 parts by weight of cranberry essence sold by senxinxiang essence technology (china) limited, 2.0 parts by weight of beta-cyclodextrin stabilizer sold by mengzhou huaxing biochemical industry limited, 3.0 parts by weight of sweetener, 0.024 parts by weight of sodium citrate acid-base regulator sold by weifang ying xuan industry limited, and water to a total amount of 100 parts by weight.
The beverage composition for conditioning dysmenorrheal is produced by the following production steps:
A) adding 80.0 parts by weight of saussurea involucrate culture, 1.65 parts by weight of ginger slices and 0.9 part by weight of purple perilla into an extraction tank, and soaking in water for 28 minutes;
B) heating and boiling the soaked substance in the step A, preserving heat for 15 minutes, adding 0.06 part by weight of double-petal roses, and preserving heat for 18 minutes; then filtering with a sand rod filter, pumping the filtrate into an extract storage tank, and heating to 60 ℃;
C) adding 0.024 part by weight of sodium citrate acid-base regulator, 0.05 part by weight of cranberry concentrated powder and 2.5 parts by weight of carob bean extract into the extracting solution obtained in the step B, and stirring for dissolving;
D) uniformly mixing 2.0 parts by weight of beta-cyclodextrin stabilizer, 0.00065 part by weight of bonito elastin peptide and 0.00075 part by weight of tremella polysaccharide, adding the mixture into the solution obtained in the step C, and stirring and dissolving the mixture; heating to 80 ℃ and keeping the temperature for 10 minutes;
E) adding 0.025 weight part of cranberry essence, stirring uniformly, and then adding water until the total amount is 100 weight parts; cooling to 45 ℃, filtering by a plate-and-frame filter, placing the obtained filtrate in a sterilization cabinet, and sterilizing at the temperature of 115 ℃ for 20 minutes to obtain the dysmenorrheal conditioning beverage composition.
Example 5: the beverage composition for conditioning dysmenorrheal
The beverage composition for conditioning dysmenorrheal comprises the following components:
0.02 parts by weight of a snow lotus culture, 0.50 parts by weight of an carob bean extract, 2.5 parts by weight of perilla, 3.25 parts by weight of ginger, 0.8 parts by weight of heavy petal rose, 0.10 parts by weight of cranberry concentrated powder, 0.0015 parts by weight of bonito elastin, 0.010 parts by weight of tremella polysaccharide, 0.03 parts by weight of rose essence sold by senxin essence science and technology (china) limited, 0.85 parts by weight of agar stabilizer sold by north fluiden biotechnology limited, 0.25 parts by weight of isomaltulose alcohol sweetener sold by shandong green health life science limited, 0.087 parts by weight of lactic acid-base regulator sold by south fluidan lactic acid science limited, and water to a total amount of 100 parts by weight.
The beverage composition for conditioning dysmenorrheal is produced by the following production steps:
A) adding 0.02 weight part of saussurea involucrate culture, 3.25 weight parts of ginger slices and 2.5 weight parts of purple perilla into an extraction tank, and soaking in water for 30 minutes;
B) heating and boiling the soaked substance in the step A, keeping the temperature for 12 minutes, adding 0.8 part by weight of double-petal roses, and keeping the temperature for 12 minutes; then filtering with a sand rod filter, pumping the filtrate into an extract storage tank, and heating to 60 ℃;
C) adding 0.087 part by weight of lactic acid-base regulator, 0.10 part by weight of cranberry concentrated powder and 0.50 part by weight of carob bean extract into the extracting solution obtained in the step B, and stirring for dissolving;
D) uniformly mixing 0.85 part by weight of agar stabilizer, 0.0015 part by weight of bonito elastin peptide, 0.010 part by weight of tremella polysaccharide and isomaltulose alcohol sweetener, adding into the solution obtained in the step C, and stirring for dissolving; adding isomaltulose alcohol sweetener to make the total amount of the sweetener reach 0.25 weight part, stirring and heating to 80 ℃, and keeping the temperature for 12 minutes;
E) adding 0.03 weight part of rose essence, stirring uniformly, and then adding water until the total amount is 100 weight parts; cooling to 45 ℃, filtering by a plate-and-frame filter, placing the obtained filtrate in a sterilization cabinet, and sterilizing at the temperature of 115 ℃ for 20 minutes to obtain the dysmenorrheal conditioning beverage composition.
Example 6: the beverage composition for conditioning dysmenorrheal
The beverage composition for conditioning dysmenorrheal comprises the following components:
0.1 part by weight of saussurea involucrate culture, 1.2 parts by weight of carob bean extract, 8.5 parts by weight of perilla, 5.0 parts by weight of ginger, 1.0 part by weight of rose, 0.4 part by weight of cranberry concentrated powder, 0.015 part by weight of bonito elastin, 0.015 part by weight of tremella polysaccharide, 0.04 part by weight of lemon essence sold by Hongtai Biotech Co., Zhuhai, 1.25 parts by weight of beta-cyclodextrin stabilizer sold by Huaxing Biochemical Co., Mengzhou, 25.0 parts by weight of isomalto-oligosaccharide sweetener sold by bowling Biotech., 0.15 part by weight of fumaric acid base regulator sold by Anhui Xue Biotech., Co., Ltd., and water to a total amount of 100 parts by weight.
The beverage composition for conditioning dysmenorrheal is produced by the following production steps:
A) adding 0.1 weight part of saussurea involucrate culture, 5.0 weight parts of ginger slices and 8.5 weight parts of purple perilla into an extraction tank, and soaking in water for 35 minutes;
B) heating and boiling the soaked substance in the step A, preserving heat for 18 minutes, adding 1.0 part by weight of double-petal roses, and preserving heat for 15 minutes; then filtering with a sand rod filter, pumping the filtrate into an extract storage tank, and heating to 60 ℃;
C) adding 0.15 part by weight of fumaric acid base regulator, 0.4 part by weight of cranberry concentrated powder and 1.2 parts by weight of carob bean extract into the extracting solution obtained in the step B, and stirring for dissolving;
D) uniformly mixing 1.25 parts by weight of beta-cyclodextrin stabilizer, 0.015 part by weight of bonito elastin peptide, 0.015 part by weight of tremella polysaccharide and isomaltose hypgather sweetener, adding the mixture into the solution obtained in the step C, and stirring and dissolving the mixture; adding isomaltose hypgather sweetener until the total amount of the sweetener reaches 25.0 parts by weight, stirring and heating to 80 ℃, and keeping the temperature for 12 minutes;
E) adding 0.04 part by weight of lemon essence, uniformly stirring, and then adding water until the total weight is 100 parts by weight; cooling to 45 ℃, filtering by a plate-and-frame filter, sterilizing the obtained filtrate by using an ultrahigh-temperature instantaneous sterilizer, filling the sterilized filtrate into a clean glass bottle, sealing the cover, spraying the sterilized filtrate by a conveyor belt through a spray cooler, spraying the sterilized filtrate by using hot water at 85 ℃ and cooling the sterilized filtrate by using warm water at 32 ℃ to obtain the dysmenorrheal-conditioning beverage composition.
Test examples: clinical observation of the conditioning dysmenorrheal beverage for improving dysmenorrheal
1.1 basic data of the experimenter
The college treatment of 150 women college students with the cold-coagulation and blood stasis type dysmenorrhea meeting the requirements of clinical standards is that the age is 19-25 years, the dysmenorrhea is generally 3-4 years, and the college treatment is randomly divided into 50 cases of a product group, 50 cases of a control group and 50 cases of a blank group. The general data of age, disease course and disease degree of three groups of patients are compared, which has no statistical significance (P > 0.05) and is comparable.
1.2 diagnostic criteria and exclusion criteria
The selected women dysmenorrhea patients all accord with the clinical diagnosis standard of 'New traditional Chinese medicine clinical research guiding principle' and 'traditional Chinese medicine gynecology', and the traditional Chinese medicine diagnosis standard of dysmenorrhea is determined: the abdominal pain usually occurs 1-2 days before menstruation with history of dysmenorrhea, and presents paroxysmal spastic pain or distending pain with feeling of falling down, and severe patients can radiate to the lumbosacral part, vagina and inner side of thigh, and faint symptoms such as pale complexion, cold sweat, cold hands and feet are seen. Patients gave their informed consent and consented to the study.
Exclusion criteria: organic diseases diagnosed by western medicine examination means, such as endometriosis, pelvic inflammatory disease, or secondary dysmenorrhea caused by cervical stenosis, and patients with severe liver, kidney, and ovary organ diseases; and patients suffering from mental dysfunction; the patient received no other treatment prior to treatment.
Clinical typing of traditional Chinese medicine diagnosis:
qi and blood deficiency type: the symptoms of dull pain in the lower abdomen during the menstrual period or after the menstruation is finished, the pain and the pressure are favored, the amount of the menstruation is small, the color is light, and the texture is thin; the patients have the symptoms of mental fatigue, pale and lusterless complexion, lassitude and inappetence, pale tongue with teeth marks, thin and white fur and thready and weak pulse.
② cold congealing and blood stasis type: the symptoms are cold pain in the lower abdomen before or during menstruation, pain caused by getting hot is relieved, tenderness is caused, the menstrual flow is small, and the color is dark and blocky; aversion to cold, cold limbs, nausea, vomiting, dark tongue, white and greasy coating, deep and tense or wiry and tense pulse. The inventor collects the patients with congealing cold and blood stasis type in the research process and carries out clinical medication observation.
1.3 methods of treatment
Product group: the drink prepared by the preparation method of the embodiment 2 of the invention is orally taken for treatment, the drink is taken one week before menstruation until the menstruation is finished, the total period is 14 days, the drink is taken orally after supper, 30ml is taken once, one time is taken once a day, 1 month is a treatment course, and 3 treatment courses are taken continuously.
Control group: the pill (Chinese medicine standard character: Z15021734, Wulanhaote Zhongmeng pharmaceutical Co., Ltd.) is orally taken with warm water, one pill at a time, one time every day, and the taking method and time are the same as those of the product group.
Blank group: when other experimental groups swallow the medicine, 30ml of warm water is drunk, and the taking method and the taking time are the same as those of the product group.
1.4 therapeutic efficacy assessment criteria
And (3) curing: when the patient feels damp in the menstruation, the lower abdomen of the patient does not feel painful, and the lumbosacral of the patient does not feel sour and painful; improvement: when the patient goes wet during menstruation, the lower abdomen pain is obviously relieved, and the lumbosacral aching sensation is obviously relieved; and (4) invalidation: the pain in the lower abdomen did not improve or worsen during menstruation. The total effective rate is (cured patient + improved patient)/case x 100%.
1.5 therapeutic results
Table 2: clinical effects of three groups of dysmenorrhea patients
The clinical experiment results listed in table 2 clearly show that the total effective rate of the product group is 98%, the effective rate of the patients with dysmenorrhea in the control group is 32%, and the total effective rate of the blank group is 10%. The cure rate of the product of the invention is 80%, the cure rate of the control group is 20%, and the cure rate of the blank group is 0. Compared with a control group and a blank group, the cure rate and the total effective rate of the product group of the invention are obviously different, and P is less than 0.01. Therefore, the conditioning dysmenorrheal drink has obvious clinical curative effect on treating the dysmenorrheal of women.
1.6 adverse reactions
The dysmenorrheal conditioning drink does not have any adverse reaction in the clinical treatment and observation process. The clinical statistical results show that the conditioning dysmenorrheal drink has the advantages of obvious clinical curative effect and eating safety in the aspect of treating the dysmenorrhea of women, and is worthy of popularization and application in clinical practice for treating the dysmenorrhea of women.
Claims (10)
1. The beverage composition for conditioning dysmenorrheal is characterized by comprising the following components: in parts by weight
2. The beverage composition for conditioning dysmenorrhea according to claim 1, wherein said beverage composition for conditioning dysmenorrhea comprises the following components: in parts by weight
3. The beverage composition for conditioning dysmenorrhea according to claim 1, wherein said beverage composition for conditioning dysmenorrhea comprises the following components: in parts by weight
4. A conditioned dysmenorrhoea drink composition according to any one of claims 1 to 3, characterized in that it comprises 0.02 to 2.0 parts by weight of stabilizer.
5. The beverage composition for conditioning dysmenorrhea according to claim 4, wherein said stabilizer is one or more selected from pectin, xanthan gum, EDTA, CMC-Na, guar gum, sodium alginate, beta-cyclodextrin, calcium alginate, acacia, gelatin and agar.
6. A conditioned dysmenorrhoea drink composition according to any one of claims 1 to 3, characterized in that it comprises 0.25 to 25.0 parts by weight of sweetener.
7. The beverage composition for conditioning dysmenorrhea of claim 6, wherein said sweetener is one or more selected from the group consisting of white granulated sugar, erythritol, xylitol, isomalt, isomalto-oligosaccharide, sucralose, acesulfame potassium, stevia and glycyrrhizin.
8. A beverage composition for conditioning dysmenorrhea according to any one of claims 1 to 3, wherein said beverage composition comprises 0.0015 to 0.15 parts by weight of an acid-base modifying agent.
9. The beverage composition for conditioning dysmenorrhea according to claim 8, wherein said pH modifying agent is one or more pH modifying agents selected from malic acid, citric acid, sodium citrate, lactic acid and fumaric acid.
10. The production method of the drink composition for conditioning dysmenorrheal is characterized by comprising the following production steps:
A) adding 0.02-80.0 parts by weight of saussurea involucrate culture, 0.05-5.0 parts by weight of ginger slices and 0.3-10.0 parts by weight of purple perilla into an extraction tank, and soaking in water for 25-35 minutes;
B) heating and boiling the soaked substance in the step A, preserving heat for 12-18 minutes, adding 0.01-6.0 parts by weight of double-petal roses, and preserving heat for 12-18 minutes; then filtering with a sand rod filter, pumping the filtrate into an extract storage tank, and heating to 60 ℃;
C) adding 0.0015-0.15 part by weight of an acid-base regulator, 0.01-1.0 part by weight of cranberry concentrated powder and 0.025-2.5 parts by weight of carob bean extract into the extracting solution obtained in the step B, and stirring for dissolving;
D) uniformly mixing 0.02-2.0 parts by weight of a stabilizer, 0.00015-0.015 part by weight of bonito elastin peptide, 0.00015-0.015 part by weight of tremella polysaccharide and a sweetening agent, adding the mixture into the solution obtained in the step C, and stirring and dissolving the mixture; adding a sweetening agent to enable the total amount of the sweetening agent to reach 0.25-25.0 parts by weight, stirring and heating to 80 ℃, and keeping the temperature for 8-12 minutes;
E) adding 0.00165-0.165 parts of edible essence, stirring uniformly, and then adding water to the total amount of 100 parts by weight; cooling to 45 ℃, filtering by a plate-and-frame filter, and sterilizing the obtained filtrate at 115 ℃ for 20 minutes to obtain the dysmenorrheal conditioning beverage composition;
or sterilizing the obtained filtrate by using an ultrahigh-temperature instant sterilizer, filling the sterilized filtrate into a clean glass bottle, sealing the cover, spraying the sterilized filtrate by a conveyor belt through a spray cooler, spraying the sterilized filtrate by hot water at 80-90 ℃ and cooling the sterilized filtrate by warm water at 25-40 ℃ to obtain the dysmenorrheal-conditioning beverage composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110593077.4A CN113317421A (en) | 2021-05-28 | 2021-05-28 | Beverage composition for conditioning dysmenorrhea and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110593077.4A CN113317421A (en) | 2021-05-28 | 2021-05-28 | Beverage composition for conditioning dysmenorrhea and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113317421A true CN113317421A (en) | 2021-08-31 |
Family
ID=77422226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110593077.4A Pending CN113317421A (en) | 2021-05-28 | 2021-05-28 | Beverage composition for conditioning dysmenorrhea and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113317421A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103549601A (en) * | 2013-11-18 | 2014-02-05 | 北京姿美堂生物技术有限公司 | Women care and nourishing beverage |
| CN105999159A (en) * | 2016-06-27 | 2016-10-12 | 深圳太太药业有限公司 | Brown sugar and saussurea involucrate composition and preparation method thereof |
| CN108936178A (en) * | 2018-07-31 | 2018-12-07 | 中科特膳（天津）医用食品有限公司 | It is a kind of for preventing and treating the solid beverage and preparation method thereof of dysmenorrhea and gynaecological imflammation |
| CN110679890A (en) * | 2019-10-28 | 2020-01-14 | 南京甘汁园糖业有限公司 | Preparation method of ginger soup for relieving dysmenorrhea |
-
2021
- 2021-05-28 CN CN202110593077.4A patent/CN113317421A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103549601A (en) * | 2013-11-18 | 2014-02-05 | 北京姿美堂生物技术有限公司 | Women care and nourishing beverage |
| CN105999159A (en) * | 2016-06-27 | 2016-10-12 | 深圳太太药业有限公司 | Brown sugar and saussurea involucrate composition and preparation method thereof |
| CN108936178A (en) * | 2018-07-31 | 2018-12-07 | 中科特膳（天津）医用食品有限公司 | It is a kind of for preventing and treating the solid beverage and preparation method thereof of dysmenorrhea and gynaecological imflammation |
| CN110679890A (en) * | 2019-10-28 | 2020-01-14 | 南京甘汁园糖业有限公司 | Preparation method of ginger soup for relieving dysmenorrhea |
Non-Patent Citations (3)
| Title |
|---|
| ALICE L: "https://www.sjgle.com/article/article_id/38810.html", 《角豆提取物 D-手性肌醇》 * |
| 张卫东等: "《延缓衰老》", 30 October 2015, 复旦大学出版社、上海科学技术出版社、上海科学普及出版社 * |
| 张新伟等: "《告别痛经36计》", 30 April 2010, 人民军医出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103416625B (en) | Barley piglet feed and preparation method thereof | |
| CN104940606A (en) | Deer-horn gelatin health product for conditioning eight types of abnormal body constitution | |
| CN104873763A (en) | Health-care product for conditioning Qi deficiency constitution | |
| CN105901715A (en) | Deer glue cake and making method thereof | |
| CN104856009A (en) | An eucommia ulmoides staminate flower health-care product | |
| CN108338258A (en) | A kind of farrowing sow Synbiotic feed additive and preparation method and application | |
| CN105454576A (en) | Jasmine-flower-comprising assorted Chinese herbal tea and preparation method thereof | |
| CN103637204A (en) | Formula of lotus seed stomach invigorating and digestion promoting soup base and production method | |
| KR20160119999A (en) | Gongjindan based on dongibogam and method of manufacturing the same | |
| CN103238757B (en) | Compound feed containing fermented cottonseed meal for chicken for eggs and preparation method thereof | |
| CN103468548A (en) | Formula and production method of ganoderma lucidum intelligence-benefiting brain-strengthening wine | |
| CN110637962A (en) | Medicine and food dual-purpose plant solid beverage for nourishing yin, warming yang and tonifying kidney | |
| CN103976211B (en) | Jelly of a kind of fat-reducing and preparation method thereof | |
| CN102511876A (en) | Hawthorn red jujube thick syrup | |
| CN105412563A (en) | Cordyceps sinensis traditional Chinese medicine liquor | |
| CN104397717A (en) | Healthy anti-constipation corn weight-losing food and making method thereof | |
| CN102160666B (en) | Natural organic beverage for moisturizing intestines, beautifying skin and prolonging life | |
| CN113317421A (en) | Beverage composition for conditioning dysmenorrhea and preparation method thereof | |
| CN100506085C (en) | Brown sugar health product capable of raising immunity of puerpera | |
| CN100382832C (en) | Health foods in use for improving symptom in climacteric period of female and fabricating method | |
| CN103520302A (en) | Sea-buckthorn leaf anti-fatigue capsule and preparation method thereof | |
| CN106978309A (en) | A kind of ginseng ant wine and preparation method and purposes | |
| CN102311905A (en) | Health-care wine and preparation thereof | |
| CN104887759A (en) | Ginseng powder wine and preparation method thereof | |
| CN110574848A (en) | Amino acid traditional Chinese medicine beverage and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210831 |
|
| RJ01 | Rejection of invention patent application after publication |